Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News and Analysis
  • Published:

Oncolytic viruses get a boost with first FDA-approval recommendation

Nature Reviews Drug Discovery volume 14, pages 369–371 (2015)Cite this article

Subjects

An Erratum to this article was published on 16 June 2015

This article has been updated

The future of cancer-killing viruses lies in their potential to augment cell and antibody immunotherapies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Change history

  • 16 June 2015

    In Table 1 of this article, the name of the oncolytic virus being developed by DNAtrix should have read 'DNX-2401'. This has been corrected in the online version of the article.

Authors
  1. Elie Dolgin
    View author publications

    You can also search for this author in PubMed Google Scholar

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dolgin, E. Oncolytic viruses get a boost with first FDA-approval recommendation. Nat Rev Drug Discov 14, 369–371 (2015). https://doi.org/10.1038/nrd4643

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4643

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research